ANEB - Substance Use Disorder Company Narrows Q2 Net Loss Reports Progress On Cannabinoid Intoxication Drug | Benzinga
The biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) reported its second quarter financial results on Tuesday for the three months ended Dec. 31, 2023,
The company's primary focus is on developing therapy for acute cannabinoid intoxication (ACI).
"Anebulo continues to make progress towards our goal of becoming the first company to have an approved treatment for acute cannabinoid intoxication," said CEO Richie Cunningham. "Our current efforts are focused on the completion of critical steps needed to support the future Phase 3 studies of selonabant, including efficient scale-up of manufacturing, completion of remaining nonclinical activities, and finalizing the designs of our proposed registrational studies for further discussion with the FDA."
See also: Substance Use Disorder Focused Anebulo Could Be Attractive Acquisition Target, Analyst Says
Q2 2024 Financial Highlights
- Total operating expenses ...